Morning Versus Bedtime Dosing of Antihypertensive Medication
A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 300 participants.
Also called NCT05089448
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 300 participants
- Sponsor
- Yan Li
- Registry
-
NCT05089448
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Recruiting
Technical summary
Registry record NCT05089448. Randomized; no masking; primary purpose treatment. Start 2021-01-28 (actual); primary completion 2026-06-30 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Morning Versus Bedtime Dosing of Antihypertensive Medication
- Condition
- Hypertension
- Condition
- Blood Pressure
- Condition
- Drug Use
- Intervention (Drug)
- Alisartan, Amlodipine besylate
- Intervention (Drug)
- Alisartan, Amlodipine besylate
- Lead sponsor
- Yan Li
Record details
- Record id
cardio:ct-nct05089448- Content hash
7fbe53e3a5beb222442c5510a13280bd77c8a5ffe0c3d3e9eb163da5617dab12